South America Pharmaceutical Contract Manufacturing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Pharmaceutical Contract Manufacturing Market Trends and Insights

Outsourcing by Domestic and Multinational Pharmaceutical Companies

Outsourcing became a strategic requirement for domestic laboratories and multinational sponsors operating in the region. Large Brazilian drug makers faced capacity constraints as production volumes increased, which spurred demand for external manufacturing partners. Blau Farmacêutica completed 2 new lines at its São Paulo complex in late 2025, and the lines entered ANVISA validation before commercial operations began in 2026. Multinational companies launching biosimilars and specialized injectable medicines also have stronger reasons to select regional partners rather than import finished products by air. Local-content preferences in public tenders and ANVISA's evolving reliance framework make qualified regional capacity more useful for market entry. The South America pharmaceutical contract manufacturing market, therefore, draws demand from domestic companies seeking sterile biologics, lyophilization, and high-potency API capabilities, as well as from multinational sponsors.

Demand for Generics, Biosimilars, and Chronic-Disease Therapies

Demand for generic drugs and biosimilars is broadening the work available to contract manufacturers. Brazil resumed domestic insulin production in July 2025 after a 20-year hiatus, through a Productive Development Partnership among Biomm, Wockhardt, and Fundação Ezequiel Dias.^{[1]Brazil Ministry of Health, “Brazil and South Korea Sign Strategic Partnerships Worth BRL 1.1 Billion,” Brazil Ministry of Health, gov.br.} This program demonstrated how technology transfer can support domestic production of a critical medicine for chronic diseases. PAHO urged countries in February 2025 to improve access to essential cancer medicines and encouraged regional approaches that can support biosimilar adoption. Contract manufacturers can therefore receive both finished-product fill-finish work for biosimilars and API batch work for lower-cost generic medicines. This combination favors providers that can offer multiple services instead of a single production step.

Rising Biologics and Injectable Localization

Biologics and sterile injectable production require substantial investment, but domestic localization has clear policy support. Brazil's Ministry of Health signed 3 Productive Development Partnerships with South Korean partners in February 2026 for technology transfer and domestic production of bevacizumab, eculizumab, and aflibercept. The first-year procurement commitment reached BRL 1.104 billion, equivalent to USD 201 million at the stated 2026 conversion rate. mAbxience operates a 24,000-liter cell culture facility in Garín, Argentina, with FDA and EMA GMP approvals, giving sponsors a South American site that can support regional and export supply. These capabilities move parts of the South America pharmaceutical contract manufacturing market beyond domestic supply and toward export-oriented biologics production. ANVISA's 2026 inspection-reliance changes can also reduce repeated inspection work for qualifying manufacturers.

Regional Supply-Chain Resilience and Import Substitution

Import dependence remains a strategic concern because Brazil sourced 90% of APIs used in pharmaceutical production from imports in 2025. The country’s pharmaceutical trade deficit reached new heights, driven by imports of immunological products, biologics, oncology medicines, and specialized biotechnology products. Brazil's health and industrial policies use Productive Development Partnerships and financing initiatives to strengthen domestic API and biologics capacity. API costs can account for up to 80% of total drug production costs, which makes local sourcing important for manufacturers serving price-sensitive generic programs. The South America pharmaceutical contract manufacturing market can benefit when suppliers build select domestic synthesis capabilities and reduce exposure to imported inputs. Quality investment remains necessary because ANVISA's risk-based certification process links renewal requirements to health-risk profiles.

GMP Compliance, Inspection, and Remediation Costs

GMP compliance is a major cost barrier for contract manufacturers in South America. ANVISA's RDC 982/2025 introduced a health risk-based model for GMP and good distribution practice certification renewal in July 2025. The framework may modernize the process, but it requires manufacturers to maintain stronger documentation and quality systems. An FDA inspection at mAbxience's Garín facility in April 2025 identified issues involving bioburden control, environmental monitoring, and validation activities. Findings at a regional site can delay technology-transfer work and lead sponsors to maintain secondary suppliers. Clean-room upgrades, equipment requalification, and repeat inspections can restrict a mid-sized facility's ability to invest in capacity expansion. Colombia's GMP requirements under Decree 335 also require rigorous process-validation records, which can challenge smaller facilities.

Currency Volatility and Imported API Dependence

Currency movements create direct uncertainty for manufacturers that buy APIs in USD or EUR while selling in local currencies. The Brazilian real showed stronger trade-weighted performance through mid-2026, but its earlier depreciation against the USD continued to affect long-term contract decisions. Argentina faced a sharper challenge because inflation and periodic currency devaluation can reduce local-currency margins. These conditions can make a contract that is competitive at signing more difficult to manage after a major exchange-rate movement. Partial domestic API sourcing can reduce the portion of costs tied to imported inputs. Brazil's drug import bill reached heightsn in the first half of 2026, and immunological products, biologics, and oncology medicines were among the fastest-rising categories.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service Type: API Chemistry Anchors Revenue While Packaging Advances

API manufacturing held 42.73% of the South America pharmaceutical contract manufacturing market share in 2025. The segment was supported by Brazil's large base of generic-drug production sites and Argentina's expanding biosimilar API capacity. Long batch runs for established molecules create predictable production schedules and cash flow for manufacturers. This helps explain why established domestic laboratories retain API capabilities while outsourcing selected dosage-form activities. Finished dosage form development and manufacturing serve companies that need formulation support, registration batches, and finished products for regional clinical programs. It also serves virtual biotechnology companies that need a supply without building their own plants.

Secondary packaging is projected to expand at a 7.98% CAGR through 2031, the highest rate within this segmentation. Serialization, tamper evidence, and country-specific labeling requirements make local packaging capacity more important to sponsors. These requirements can make centralized packaging in Europe or North America less suitable for products intended for several South American countries. Unither Pharmaceuticals operates 2 GMP-certified facilities in Brazil and holds authorizations from ANVISA, INVIMA, and DIGEMID.^{[2]Unither Pharmaceuticals, “Regulatory Authorizations and Certifications,” Unither Pharmaceuticals, unither-pharma.com.} Its footprint illustrates why multi-country packaging and regulatory capabilities can create an advantage. The South America pharmaceutical contract manufacturing market gives packaging providers a larger role when sponsors need market-ready, locally compliant units.

By Drug Molecule Type: Small Molecules Lead While Advanced Therapies Gain Ground

Small molecules accounted for 56.83% of the South America pharmaceutical contract manufacturing market size in 2025. Their position reflected the established generics base and chemistry infrastructure across São Paulo's pharmaceutical corridor. Public procurement through Brazil's Unified Health System supports high-volume demand for off-patent medicines. The manufacturing chain serving this demand remains largely focused on small-molecule products. Providers with validated chemistry processes and efficient batch operations can continue to serve this broad volume base. The segment also gives manufacturers a foundation for investments in more complex product classes.

Advanced therapies are projected to expand at a 7.78% CAGR through 2031, making them the fastest-growing molecule category. Cell and gene therapies started from a narrower base than conventional molecules, so individual capacity decisions can materially shape development in the category. Biologics also have a growing role, as regional production of biosimilar monoclonal antibodies and recombinant proteins can support both local and export supply. ITC-CDMO offers GMP-compliant services for cell-based therapies and has supported clinical-phase projects.^{[3]ITC-CDMO, “GMP-Compliant CDMO Services,” ITC-CDMO, itc-cdmo.com.} This activity shows that the South America pharmaceutical contract manufacturing market has early-stage capacity for advanced modalities. Sponsors can consider regional providers for clinical manufacturing when their quality and technical requirements are met.

By Scale of Operation: Commercial Manufacturing Leads While Clinical Capacity Expands

Commercial-scale manufacturing commanded 61.62% of 2025 revenue in the scale-of-operation segment. Routine production of established generics and biosimilars for domestic use and regional exports supported this share. High equipment use and existing validation packages provide cost advantages in commercial production. Long-established producers such as Eurofarma Laboratórios and Blau Farmacêutica have built these capabilities over many years. Eurofarma began operations at its Montes Claros complex in October 2025, covering 515,000 m² and including 250,000 m² of built infrastructure. The modular design gives the company room to add capacity as demand changes.

Clinical-phase manufacturing is projected to expand at a 7.73% CAGR through 2031. Virtual biotechnology companies and regional trial sponsors increasingly need local GMP lot production instead of importing investigational materials from North America or Europe. São Paulo State University opened a pilot-scale biopharmaceutical factory in 2025 with BRL 20 million (USD 3.4 million at the stated 2025 rate) from the Ministry of Health, and BRL 60 million (USD 10.2 million) planned for equipment. The facility was designed to support academic and clinical research in biotechnology. Public investment treats clinical manufacturing as scientific infrastructure as well as a commercial service. That approach can support private partnerships and cost-sharing arrangements for smaller sponsors.

By End User: Big Pharma Holds Spending While Virtual Biotech Expands

Big Pharma accounted for 45.82% of end-user spending in 2025. Long-duration contracts for established products and regional portfolio launches supported this position. These contracts often cover multiple countries and require demanding quality standards. Preferred-supplier arrangements also give established contract manufacturers an advantage in retaining accounts. Generic pharmaceutical companies remain important users, as they require high volumes of oral solid dosage forms and injectables. Brazilian laboratories produced 8 of every 10 medicines sold at retail in Brazil during 2025, reinforcing the domestic demand base for manufacturing services.

Emerging and virtual biotech is projected to expand at a 7.83% CAGR through 2031, the fastest rate among end-user groups. These sponsors commonly have 1 or 2 clinical programs and no internal production facilities. They need integrated support from process development through GMP lot manufacturing. The segment is linked to biotechnology incubators and venture-backed companies in São Paulo and Buenos Aires. In 2025, FIFARMA reported that South American countries were becoming more attractive for biomedical investment, while market access and regulatory predictability remained challenges. The South America pharmaceutical contract manufacturing market can gain work from this group when providers offer flexible, integrated programs.

By Therapeutic Area: Oncology Maintains Scale While CNS Therapies Accelerate

Oncology held 38.72% of 2025 revenue in the therapeutic area segment. Cancer remains a major cause of illness and death across the region, and PAHO and WHO reported nearly 1.5 million new cancer cases and more than 750,000 cancer deaths in the region during 2024.^{[4]Pan American Health Organization and World Health Organization, “WHO Calls for Urgent Action as New Cancer Cases Are Projected to Nearly Double by 2050,” Pan American Health Organization, paho.org.} High-potency API containment for cytotoxic products and aseptic fill-finish for monoclonal antibodies require specialized expertise from qualified providers. Brazil's February 2026 technology-transfer partnerships included bevacizumab and aflibercept, which added domestic production support for cancer biologics. These requirements support demand for facilities with strong containment and sterile manufacturing capability.

CNS therapies are projected to expand at a 7.22% CAGR through 2031. Psychiatric drug purchases in Brazil increased 25% during the 3 years ending in August 2025. Antipsychotic and attention-deficit/hyperactivity disorder categories increased over the same period. This demand can increase the need for controlled-substance formulation and primary packaging capabilities. Cardiovascular and infectious-disease medicines also remain part of the therapeutic mix. Public health needs in Peru, Colombia, and Bolivia sustain demand for antiparasitic and antimicrobial APIs. The South America pharmaceutical contract manufacturing market must also track Brazil's CONITEC technology assessment process because formulary decisions can shape public procurement batch volumes.

Geography Analysis

Brazil held 48.73% of the South America pharmaceutical contract manufacturing market share in 2025. Its leading position rests on an established pharmaceutical infrastructure, a broad base of GMP-certified facilities, and ANVISA's alignment with international inspection practices. Eurofarma's October 2025 opening of the Montes Claros complex reflected continuing confidence in Brazil as a regional production hub. Brazil's retail pharmaceutical revenue reached BRL 146.8 billion, equivalent to USD 25 billion at the stated 2025 rate, and domestic producers generated BRL 5.80 of every BRL 10 in revenue. This domestic demand supports contract services, although imported APIs can weaken cost competitiveness when the real depreciates.

Argentina and Chile represent the next strategic hubs for the South America pharmaceutical contract manufacturing market. Argentina has biologics-capable facilities, including MABXIENCE'S Garín site with 24,000 liters of cell culture capacity and FDA and EMA GMP approvals. Sinergium Biotech also supported regional COVID-19 vaccine supply through its manufacturing capabilities. Argentina's regulatory expertise supports pharmaceutical production, although macroeconomic instability and currency controls can affect investment schedules and contract pricing. Chile is projected to expand at a 7.22% CAGR through 2031, and its 2025 and 2026 GMP updates for pharmaceutical water, sterile products, and biologics provide a clearer framework for qualified sites.

Colombia, Peru, and the rest of South America offer longer-term expansion opportunities. Colombia's INVIMA has expanded its GMP certification scope under Decree 335, and Unither holds authorization to supply the Colombian market from Brazil. Peru's DIGEMID increasingly accepts inspections from recognized authorities, which can help sponsors use existing GMP documentation. Bolivia, Ecuador, and other countries still rely heavily on imported finished products, while public procurement rules are beginning to encourage regional sourcing.